Status:
COMPLETED
Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream, Hydrocortisonacetat 1% Cream, Betamethasonvalerat 0,1% Cream and Clobetasol-17-propionat 0,05% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound
Lead Sponsor:
Technische Universität Dresden
Conditions:
Healthy
Eligibility:
All Genders
18-40 years
Phase:
PHASE1
Brief Summary
to compare the atrophogenic potentials of pimecrolimus 1% cream, hydrocortisonacetat 1% cream, betamethasonvalerat 0,1% cream and clobetasol-17-Propionat 0,05% cream
Eligibility Criteria
Inclusion
- male and female probands age between 18-40 years
- skin healthy
- skintype I-III according to Fitzpatrick
Exclusion
- women of childbearing potential without adequate contraception
- pregnant or breastfeeding
- genetic defect of epidermal barrier
- external or systemic treatment with drugs, which probably have an effect to the thickness of skin or to the production of teleangiektasien within the last 6 month before study entry
- skin disease, which hinder the evaluation with OCT, ultrasound or dermaphot
- UV treatment within the last 4 weeks before study entry
- participation to another clinical trial within the last 30 days before study entry
- allergy against pimecrolimus or hydrocortison or betamethasonvalerat or Clobetasol-17-propionat
- severe systemic diseases; ongoing immunosuppressive treatment
- planned vaccination should realize before study entry or 28 days after end of treatment
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00655512
Start Date
January 1 2008
End Date
October 1 2008
Last Update
June 11 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Dermatology, Medical Faculty, TU Dresden
Dresden, Germany